ESUI15
#ESUI15
Imaging and Individualised Medicine
4th Meeting of the EAU Section of Urological Imaging In conjunction with the 7th European Multidisciplinary Meeting on Urological Cancers
12 November 2015, Barcelona, Spain
Jurgen Futterer (NL), ESUI Ex-Officio
Imaging in prostate cancer: MRI’s role to expand in the next decade The role of imaging techniques such as multiparametric Magnetic Resonance Imaging (MP-MRI) will expand in the next few years and will have a more central role in the diagnosis of prostate cancer (PCa), particularly in cases where new technologies are combined to yield more detailed images.
MRI? Mandatory sequences and PIRADS 2.0.” The lecture is part of a PointCounterpoint session where experts will debate on whether MRI detects significant prostate cancers. ESUI Chairman Jochen Walz (FR) will present counter arguments while Dr. H.U. Ahmed (GB) would argue in favor of MRI.
“MP-MRI will play an important role in guiding both biopsy as well as focal therapy,” said radiologist Dr. Jurgen Futterer of the Radboud UMC in Nijmegen (NL). Futterer will lecture during the upcoming 4th Meeting of the EAU Section of Urological Imaging (ESUI) on November 12 in Barcelona, Spain. The 4th ESUI will be held in conjunction with the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC).
Futterer will discuss the essential imaging sequences (T2-weighted anatomical imaging, diffusion weighted imaging and contrast enhanced MR imaging) in his lecture, highlighting the role of each procedure. He will also look into the role and application of PI-RADS v2, the second and revised version of Prostate Imaging-Reporting and Data System (PI-RADS) which refers to a structured reporting scheme for prostate cancer.
“MP-MRI can detect clinical significant cancers in males with rising PSA and negative biopsies. The negative predictive value is around 95% (this is based on a recent systematic review in European Urology). However, non-significant cancers may be missed (Gleason 6 cancers). MP-MRI can be applied in patients who are opting for active surveillance and active treatment follow-up,” explained Futterer when asked how doctors can achieve optimal treatment results.
With the emphasis on sophisticated imaging techniques in recent years, Futterer said he expects to see new developments which will eventually impact PCa diagnosis.
“Moreover, MP-MRI can be used to select patients for focal therapy,” he added while underscoring that optimal PCa treatment will increasingly rely on imaging results and capabilities. Futterer will lecture on the topic “What is the new standard of prostate
Jochen Walz (FR), ESUI Chairman
In current guidelines, according to Futterer, MP-MRI is recommended in certain indications. “I think that imaging has a more prominent role,” he noted given the fact the doctors need a tool that will allow them to draw more informed conclusions, enabling optimal treatment strategies. Regarding challenges in the field of imaging for urological cancers, he noted the role of prostate-specific membrane antigen (PSMA) PET imaging in detecting lymph node metastasis. “Currently, imaging is limited for lymph node metastases,” he said implying that experts need to further look into the role of PSMA. The ESUI Meeting has prepared an exciting programme which will cover the most recent developments in urological imaging, with topics up for discussion and debate in a number of roundtable sessions. The day-long agenda will take up individualised medicine, new imaging technologies on the horizon, molecular imaging (in a joint session with the European Association of Nuclear Medicine) and optimising PC a management, among other topics.
“Most likely diffusion weighted imaging will evolve into a biomarker for cancer aggressiveness. Furthermore, finger printing imaging techniques will be available in which from one MR imaging sequence acquisition we will able to extract different tissue contrast,” he said. Before this happens, however, more research into the exact role of imaging needs to be done, particularly in the multi-disciplinary setting where various prostate cancer experts are involved in the treatment management.
For programme information and registration details, visit the event website at www.esui15.org
Patient Information Essential tool in your practice
Credit Registry Reports electronically! EU-ACME members may generate and print Credit Registry Reports online.
• Jargon-free
If you do not wish to receive hard copy of the CRR please log in to your online account and check the box “I will generate and print my CRR online. I do not wish to receive a copy by regular mail”.
• Evidence-based • Clear illustrations
Make sure we have your up-to-date address details! Log in to your My-EAU account on uroweb.org to update your e-mail and correspondence addresses. www.uroweb.org/My-EAU
www.eu-acme.org
• Multiple languages • Available on and offline
Grab hold of the possibilities.
Perc NCircle® Nitinol Tipless Stone Extractor
Learn more at: patients.uroweb.org
Perc NGage® Nitinol Stone Extractor
www.cookmedical.com
Perc NCompass® Nitinol Stone Extractor
Some products or part numbers may not be available in all markets. Contact your local Cook representative or Customer Service for details. © COOK 12/2014
28
European Urology Today
D13907-EN
August/September 2015